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Summary
Background Dopamine transporter deﬁ ciency syndrome is the ﬁ rst identiﬁ ed parkinsonian disorder caused by genetic 
alterations of the dopamine transporter. We describe a cohort of children with mutations in the gene encoding the 
dopamine transporter (SLC6A3) with the aim to improve clinical and molecular characterisation, reduce diagnostic 
delay and misdiagnosis, and provide insights into the pathophysiological mechanisms.
Methods 11 children with a biochemical proﬁ le suggestive of dopamine transporter deﬁ ciency syndrome were enrolled 
from seven paediatric neurology centres in the UK, Germany, and the USA from February, 2009, and studied until 
June, 2010. The syndrome was characterised by detailed clinical phenotyping, biochemical and neuroradiological 
studies, and SLC6A3 mutation analysis. Mutant constructs of human dopamine transporter were used for in-vitro 
functional analysis of dopamine uptake and cocaine-analogue binding.
Findings Children presented in infancy (median age 2·5 months, range 0·5–7) with either hyperkinesia (n=5), 
parkinsonism (n=4), or a mixed hyperkinetic and hypokinetic movement disorder (n=2). Seven children had been 
initially misdiagnosed with cerebral palsy. During childhood, patients developed severe parkinsonism-dystonia 
associated with an eye movement disorder and pyramidal tract features. All children had raised ratios of homovanillic 
acid to 5-hydroxyindoleacetic acid in cerebrospinal ﬂ uid, of range 5·0–13·2 (normal range 1·3–4·0). Homozygous or 
compound heterozygous SLC6A3 mutations were detected in all cases. Loss of function in all missense variants was 
recorded from in-vitro functional studies, and was supported by the ﬁ ndings of single photon emission CT DaTSCAN 
imaging in one patient, which showed complete loss of dopamine transporter activity in the basal nuclei.
Interpretation Dopamine transporter deﬁ ciency syndrome is a newly recognised, autosomal recessive disorder related 
to impaired dopamine transporter function. Careful characterisation of patients with this disorder should provide 
novel insights into the complex role of dopamine homoeostasis in human disease, and understanding of the 
pathophysiology could help to drive drug development.
Funding Birmingham Children’s Hospital Research Foundation, Birth Defects Foundation Newlife, Action Medical 
Research, US National Institutes of Health, Wellchild, and the Wellcome Trust.
Introduction
Dopaminergic neurons expressing the dopamine 
transporter (DAT) are located predominantly in the 
substantia nigra pars compacta, with projections to the 
striatum via the nigrostriatal pathway, and in the ventral 
tegmental area of the midbrain, with mesocorticolimbic 
projections to the nucleus accumbens, hippocampus, 
and other corticolimbic structures.1 Consistent with this 
cerebral distribution, dopamine has a wide variety of 
important physiological functions including motor 
control, cognition, and behaviour.2–4 Defects in the 
dopamine biosynthetic pathway (webappendix p 1) result 
in complex, predominantly extrapyramidal neurological 
disorders.5 DAT has an important homoeostatic role in 
dopaminergic transmission, and variants of the gene 
encoding DAT (SLC6A3) and other factors causing 
dopamine dysregulation have been implicated in several 
neurological and neuropsychiatric diseases.6,7
A syndrome of infantile parkinsonism-dystonia and 
raised dopamine metabolites in cerebrospinal ﬂ uid (CSF) 
has been described,8 and we have previously reported 
three children with this phenotype in whom we identiﬁ ed 
loss-of-function mutations in SLC6A3 (gene locus 5p15.3).9 
To delineate this novel disorder, dopamine transporter 
deﬁ ciency syndrome, we describe the clinical, 
biochemical, molecular genetic, and functional aspects 
of 11 children with germline SLC6A3 mutations.
Methods
Patients
11 children with suspected dopamine transporter 
deﬁ ciency syndrome were enrolled from seven paediatric 
neurology centres in the UK, Germany, and the USA. 
These patients were identiﬁ ed by contact with paediatric 
neurologists specialising in movement disorders or 
neurotransmitter diseases, and liaising with specialist 
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laboratories doing paediatric CSF neurotransmitter 
analysis (Institute of Child Health, London, UK; Medical 
Neurogenetics, Atlanta, GA, USA; University Children’s 
Hospital, Heidelberg, Germany; Kinderspital, Zurich, 
Switzerland). Potential patients were also identiﬁ ed by 
searching PubMed for published clinical cases. Patients 
were enrolled into the study from February, 2009, 
onwards and the clinical phenotype was assessed at 
regular intervals thereafter; the cutoﬀ  date for inclusion 
of data in this report was June, 2010. A brief overview of 
the clinical phenotype of patients 1–3 was reported in 
association with the initial identiﬁ cation of SLC6A3 
mutations in 2009,9 and the clinical features of 
patients 4–6 were brieﬂ y reported in 2004.8 The study 
research protocol was approved by local research ethics 
committees and written informed consent was obtained 
for participating individuals from their next of kin.
Procedures
All children were clinically assessed by a paediatric 
neurologist. Video footage documenting the clinical 
features of patients from early infancy to present time 
was obtained either by their parents (in their home 
environment) or by the examining paediatric neurologist 
(during a clinic or hospital appointment). The duration 
of video footage obtained, and the intervals between video 
recordings, varied between patients. Acquired clinical 
videos were reviewed independently by three paediatric 
neurologists in June, 2010. Medical case notes were 
reviewed to establish the clinical history, pattern of 
disease evolution, and response to drug treatment.
CSF neurotransmitter analysis was done in all patients, 
and concentrations of homovanillic acid and 
5-hydroxyindoleacetic acid were measured by use of 
laboratory-speciﬁ c age-related reference ranges.10–12 
Homovanillic acid and 5-hydroxyindoleacetic acid are the 
stable degradation products of dopamine and serotonin, 
respectively, and thus are indicative of the turnover of 
dopamine and serotonin.13,14 Urine catecholamine 
metabolites, serum prolactin, and serum creatine kinase 
were analysed. We also did neuroradiological studies: MRI 
in all patients; magnetic resonance spectroscopy (MRS) in 
patients 1, 2, and 11; and nuclear brain imaging with single 
photon emission CT DaTSCAN (GE Healthcare, 
Amersham, UK) in patient 3 after administration of 
the DAT ligand ioﬂ upane (¹²³I-2β-carbometoxy-
3β-[4-iodophenyl]-N-[3-ﬂ uoropropyl] nortropane).
In molecular genetic studies, all annotations and 
physical positions were recorded as in the National 
Centre for Biotechnology Information’s genome build 
(version 36.3). Analysis of the SLC6A3 gene was done by 
direct sequencing as described previously.9 Long-range 
PCR was used to identify the deletion breakpoint in 
patient 8 (webappendix p 2).
Mutant constructs of human DAT (hDAT) were prepared 
from wild-type pCIN4-hDAT.9 The primers and their 
complementary primers are described in webappendix p 3. 
Culturing and transient transfection of HEK293 cells with 
mutant and wild-type hDAT was done by use of 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) as 
previously described.9 Uptake of ³H-dopamine into cells 
expressing hDAT was measured for 5 min at 21°C, and to 
monitor cocaine-analogue binding, cells were incubated 
with 4 nM ³H-CFT (2β-carbomethoxy-3β-[4-ﬂ uorophenyl]-
tropane) for 20 min at 21°C; for saturation analysis, 
0·1–100 nM non-radioactive CFT was also present.9 All 
other methods and analyses were as described by us 
previously.9 Brieﬂ y, uptake and binding assays used a high 
sodium, low potassium buﬀ er containing glucose and 
tropolone, and the non-speciﬁ c binding was deﬁ ned as 
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Sex Age (years) Age at 
clinical 
presentation 
(months)
Early motor features 
present at disease onset
Early motor features developing 
before 3 years of age
Motor features developing 
after 3 years of age
EMD BD MCP Maximum 
ratio of 
HVA to 
HIAA
PHF* Dk† Dt AH PHF* Dk† Dt AH PTF MDD‡ PHF* Dt PTF MDD‡
Patient 1 M 5·7 0·75 Yes No No Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes 13·2
Patient 2 F 4·2 3 Yes No No Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes 6·8
Patient 3 F 11·4 5 Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 12·5
Patient 4 F 16·2 (died) 4 Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No 12·1
Patient 5 F 8·9 (died) 4 Yes No No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 11·4
Patient 6 M 15·0 (died) 2·5 Yes No No No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No 12·1
Patient 7 F 14·2 (died) 1·5 No Yes Yes No Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes 6·6
Patient 8 F 2·0 0·5 No No Yes Yes Yes No Yes Yes No Yes NA NA NA NA Yes Yes Yes 8·6
Patient 9 F 6·0 3 No No Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 12·9
Patient 10 F 1·9 7 No Yes No Yes Yes§ Yes Yes Yes No Yes NA NA NA NA Yes Yes No 10·5
Patient 11 F 4·3 0·5 No No Yes No Yes No Yes Yes No Yes Yes Yes No Yes No Yes No 11·0
EMD=eye movement disorder. BD=bulbar dysfunction. MCP=misdiagnosis with cerebral palsy. HVA=homovanillic acid. HIAA=5-hydroxyindoleacetic acid. PHF=parkinsonian hypokinetic features. Dk=dyskinesia. 
Dt=dystonia. AH=axial hypotonia. PTF=pyramidal tract features. MDD=motor developmental delay.  M=male. F=female. NA=not applicable (patient younger than 3 years). *Bradykinesia, rigidity, tremor, or 
hypomimia. †Chorea or restlessness. ‡Delay in gross motor skills. §Hypomimia only.
Table 1: Overview of clinical features of dopamine transporter deﬁ ciency syndrome
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1 μM CFT. The binding aﬃ  nity (Kd) and maximum 
binding of ³H-CFT were estimated with non-linear 
regression by use of Radlig software (KELL program). Half 
maximal inhibitory concentration was estimated by 
logistic ﬁ tting with ORIGIN software (OriginLab), and 
this value was then inputted into the Cheng-Prusoﬀ 
equation to calculate the potency (Ki) of dopamine in 
inhibition of ³H-CFT binding.
Statistical analysis
Binding results for wild-type and mutant DAT were ﬁ rst 
compared by one-way ANOVA. If this test indicated 
signiﬁ cant diﬀ erences between groups, the Dunnett 
multiple comparisons test was used to compare each 
mutant value with wild type. We regarded p values of 
0·05 or lower as signiﬁ cant. Two sets of experiments were 
done: wild-type DAT (controls) were compared with 
mutants (Leu368Gln and Pro395Leu) for patients 1–3;9 
and wild-type DAT (controls) were compared with mutants 
(Pro554Leu, Gly327Arg, Gly327Arg plus Gln439X, 
Pro529Leu, Leu224Pro, and Arg521Trp) for patients 4–11. 
Val158Phe was not included in the statistical analysis 
because no binding was detectable. Samples consisted of 
three to ﬁ ve independent experiments for which mean (SE) 
was calculated; because two sets of experiments were 
done, we calculated the combined mean (SE) for controls 
from eight to nine independent experiments. In each 
experiment, binding assays were done in triplicate on cell 
preparations expressing either the wild-type or mutant 
DAT construct. ANOVA and Dunnett statistical tests were 
applied to each set separately.
Role of the funding source
The funding sources had no role in the study design, 
data collection, data analysis, data interpretation, writing 
of the report, or the decision to submit for publication. 
All authors had full access to all data in the study. The 
corresponding author (MAK), MEAR, and ERM had ﬁ nal 
responsibility for the decision to submit for publication.
Results
11 children (two boys, nine girls) with dopamine 
transporter deﬁ ciency syndrome were enrolled into the 
study. All children presented with a movement disorder 
with onset in early infancy (median age 2·5 months, range 
0·5–7; table 1). Seven children were alive at the time of 
writing this report (age range 1·9–11·4 years). Before 
diagnosis, seven children had been misdiagnosed with 
cerebral palsy (patients 1–3, 5, and 7–9). None of the 
children had a family history of Parkinson’s disease, or 
movement or neuropsychiatric disorders. Neonatal 
irritability and early feeding diﬃ  culties were evident in six 
children (patients 1–4, 8, and 11). Five children presented 
mainly with hyperkinetic symptoms (dystonia, chorea, 
dyskinesia; patients 7–11), four had predominantly 
hypokinetic and parkinsonian features (patients 1, 2, 5, 
and 6), and two (patients 3 and 4) had a mixed hyperkinetic 
and hypokinetic movement disorder. Axial hypotonia was 
evident in eight children on presentation (patients 1–5 
and 8–10).
Clinical features of dopamine transporter deﬁ ciency 
syndrome included infantile hyperkinesia (webvideos 1 
and 2), orolingual dyskinesia (webvideo 1, clip 2), dystonia 
(webvideo 3), parkinsonian features (webvideos 4–7), 
pyramidal tract features, axial hypotonia, and eye 
movement abnormalities (webvideo 8).
An early hyperkinetic movement disorder was seen in 
six patients (patients 3–7 and 10). Two patients presented 
with repetitive generalised choreiform movements of 
variable amplitude (patients 7 and 10; webvideo 2), and a 
further four developed choreiform movements of the 
lower limbs within a year of presentation (patients 3–6). 
As these six patients increased in age to 2–4  years, 
hyperkinesia reduced gradually during childhood. 
Orolingual dyskinesia was recorded in six children 
(patients 1, 3–5, 8, and 10).
Generalised dystonia was recorded in all children: in 
six at symptom onset (patients 3, 4, 7–9, and 11), and 
within 1 year of clinical presentation in the remaining 
children (patients 1, 2, 5, 6, and 10). All children had 
oromandibular dystonia, eight had bilateral striatal toe 
(patients 3–9 and 11), ﬁ ve had prominent upper-limb 
dystonia (patients 1 and 3–6), characterised by dystonic 
posturing of the arms, and seven had recurrent episodic 
dystonic crises (patients 3–5, 7–9, and 11), characterised 
by severe generalised dystonia. In many, dystonic crises 
were managed at home by the parents (eg, with 
benzodiazepines), but sometimes needed hospital 
admission (patient 5). Patient 9 had episodic status 
dystonicus, with severe generalised dystonia, oculogyric 
crises, irritability, hyperthermia (either due to an 
intercurrent infection or secondary to status dystonicus), 
diaphoresis, marked rigidity, reduced consciousness, 
raised serum creatine kinase, severe rhabdomyolysis, 
and abnormal liver function tests. These episodes lasted 
up to several hours, and required hospital admission and 
sometimes intensive care treatment.
Figure 1: Nuclear brain imaging with single photon emission CT DaTSCAN in a control patient (A), a patient 
with juvenile parkinsonism of unknown aetiology (B), and patient 3 (C)
Patients were age-matched. (A) Normal distribution of dopamine transporter sites. (B) Bilateral symmetrical loss 
of dopamine transporter sites from lentiform nuclei. (C) Complete loss of dopamine transporter sites in the basal 
nuclei, resulting in high background counts without any activity from basal nuclei.
A B C
See Online for webvideos
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Parkinsonian features eventually became evident in 
all children. Six had generalised bradykinesia from 
disease onset (patients 1–6), and four developed this 
feature 1–30 months after presentation (patients 7–9 
and 11). Generalised rigidity was a presenting feature in 
four children (patients 1, 3, 4, and 10), and developed in 
a further six patients within 1 year of symptom onset 
(patients 2, 5–7, 9, and 11). Cogwheeling rigidity was 
evident in four patients (patients 1–3 and 6). All children 
developed hypomimia, at a mean of 7 months 
(range 2–18) after presentation. A coarse, predominantly 
resting distal tremor was noted in eight children, three 
at presentation (patients 1, 3, and 4) and ﬁ ve at 
2–36 months after presentation (patients 2, 5–7, and 9). 
Although the dystonia and rigidity complicated the 
assessment of resting tone, none of the children had 
pyramidal tract features at presentation. However, eight 
children (patients 1–7 and 9) developed pyramidal signs 
in early childhood of sustained ankle clonus, increased 
adductor tone, and increased four-limb hypertonicity 
when asleep. So far, three children younger than 5 years 
(patients 8, 10, and 11) have had no signs of pyramidal 
tract abnormality.
Axial hypotonia was noted at presentation in eight 
patients (patients 1–5 and 8–10), and developed within 
1 year of clinical presentation in all other children 
(patients 6, 7, and 11). Eight children developed an eye 
movement disorder with ocular ﬂ utter, three at 
presentation (patients 4, 8, and 10) and ﬁ ve within 
4–44 months after disease onset (patients 3, 5–7, and 9), 
which was conﬁ rmed by electronystagmography in 
patients 4 and 7. Six of these patients had saccade 
initiation failure and slow saccadic eye movements 
(patients 3–7 and 10), and two had eyelid myoclonus 
(patients 3 and 7). Oculogyric crises were common in 
patients 8 and 9.
The disease course aﬀ ects motor and cognitive 
development, and is associated with secondary medical 
complications and reduced life expectancy. All children 
had severe gross motor delay. Progressive dystonia 
resulted in severe ﬁ xed postural dystonia, particularly 
aﬀ ecting the upper limbs. Parkinsonian symptoms also 
progressed, resulting in akinesia, severe rigidity, obvious 
facial hypomimia, and prominent tremor. Although the 
presence of diurnal variation was diﬃ  cult to assess in 
infants and young children, all patients older than 3 years 
did not show diurnal ﬂ uctuation of extrapyramidal 
symptom severity. Despite severe motor impairment, 
cognitive skills did not seem to be so severely aﬀ ected. 
None of the children was able to speak, but despite absent 
expressive language, attributed mainly to motor deﬁ cit, 
most children had good receptive language and situational 
understanding. Many children developed methods of 
non-verbal communication, such as head and eye 
pointing techniques, and communication aids using eye 
gaze (eg, Tobii device). Formal neuropsychological 
assessment in patient 3 at age 11·3 years showed cognitive 
sparing relative to the patient’s severe motor impairment 
(webappendix p 4). All children developed gastrointestinal 
complications, such as gastro-oesophageal reﬂ ux, 
constipation, excessive drooling, choking, feeding 
diﬃ  culties, and failure to thrive. Sleeping diﬃ  culties, 
orthopaedic complications, and frequent pneumonias 
were also prevalent. Four children (patients 4–7) have 
died (age range 8·9–16·2 years) secondary to respiratory 
complications and cardiac failure.
Although physicians attempted several drug treatments 
(including muscle relaxants, and dopaminergic, 
anticholinergic, antiglutaminergic, and γ-aminobutyric 
acid [GABA]-ergic agents), and surgical intervention 
(deep brain stimulator in patient 3), most treatments 
were either ineﬀ ective or provided a partial or temporary 
Ethnic origin Parental 
consanguinity
Mutation status Mutations in DNA Exon Eﬀ ect on protein 
product
Patient 1 Pakistani Yes Homozygous 1103T→A 8 Leu368Gln
Patient 2 Pakistani Yes Homozygous 1103T→A 8 Leu368Gln
Patient 3 Mixed European descent Yes Homozygous 1184C→T 9 Pro395Leu
Patient 4 Mixed European descent No Homozygous 1156+5delG Intron 8 splice site Unknown
Patient 5* Mixed European descent No Compound heterozygous 472G→T
1661C→T
4
13
Val158Phe
Pro554Leu
Patient 6 Turkish Yes Homozygous 1031+1G→A Intron 7 splice site Unknown
Patient 7* Mixed European descent Yes Homozygous 399delG 3 Ile134SerfsX5
Patient 8 Mixed European descent No Homozygous 1499_1767del 12, 13 Gly500GlufsX13
Patient 9 Mixed European descent No Compound heterozygous 
(three variants)
979G→A
1315C→T
1586C→T
7
10
12
Gly327Arg
Gln439X
Pro529Leu
Patient 10 Mixed European descent Yes Homozygous 671T→C 5 Leu224Pro
Patient 11 Mixed European descent Yes Homozygous 1561C→T 12 Arg521Trp
*DNA not available for proband who had died some years before the study; both parents were heterozygous for the described mutations.
Table 2: SLC6A3 mutations identiﬁ ed in patients with dopamine transporter deﬁ ciency syndrome
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clinical response. Nine patients (patients 1–6 and 9–11) 
received levodopa combined with carbidopa (cocareldopa), 
with maximum doses of 2–6 mg/kg per day for a 
minimum of 2–3 weeks. Seven children (patients 1–6 
and 10) had no clinical response, and treatment was 
limited by intolerable side-eﬀ ects in four children 
(patients 4–6 and 10). In patients 9 and 11, doses of about 
2 mg/kg per day improved upper-limb motor function 
and facial expression, and abolished episodic dystonic 
crises, but the dose could not be further increased 
because both patients developed drug-induced 
dyskinesias at higher doses. Subsequent addition of the 
dopamine agonist ropinirole in these patients led to 
further improvement of motor symptoms. After genetic 
diagnosis, ropinirole treatment was started in patient 3 at 
age 10·5 years, leading to reduced parkinsonian features, 
increased facial expression, an improved feeding pattern, 
and a mild reduction in upper-limb bradykinesia. The 
dopamine agonist pramipexole was ineﬀ ective in patient 4 
at age 6 years and patient 10 at age 1·5 years, but resulted 
in some clinical improvement of bradykinesia and 
dystonia in patient 8 from age 15 months onwards.
CSF neurotransmitter analysis showed that all children 
had a raised ratio of homovanillic acid to 
5-hydroxyindoleacetic acid of range 5·0–13·2 (normal 
range about 1·3–4·0; webappendix p 5). Excretion of 
urine homovanillic acid was slightly increased in six of 
seven children investigated, with range of 22–47 μmol 
homovanillic acid per mmol creatine (normal range 
2–15 μmol homovanillic acid per mmol creatine). Serum 
prolactin was measured in seven patients (patients 1–4 
and 7–9), and was raised in patients 2 and 3. Raised 
activity of serum creatine kinase, with further increase 
during dystonic crises, was recorded in six children, with 
range of 242–1773 IU/L (normal range 24–173 IU/L).
After genetic diagnosis, DaTSCAN imaging in patient 3 
at age 10 years showed complete loss of DAT activity in 
the basal nuclei, with high background counts on the 
image (ﬁ gure 1). Although few paediatric data are 
available for comparison, the high background counts 
recorded have also been noted in adult patients with poor 
uptake in the basal nuclei, and could be attributed to 
unbound DaTSCAN in the blood pool (TL, personal 
communication). Loss of DAT activity in patient 3 was 
more extensive than in a patient aged 9·2 years with 
juvenile parkinsonism of unknown aetiology (not 
dopamine transporter deﬁ ciency syndrome) who had 
symmetrical reduction of DAT activity in the basal nuclei 
(ﬁ gure 1). On brain MRI, no patients had gross structural 
defects or signal abnormalities in the basal ganglia. Eight 
children (patients 1, 3, 4, and 6–10) had subtle 
neuroradiological abnormalities, such as prominence of 
the external frontotemporal subarachnoid spaces and 
mild delay in myelination. Patient 9 had a white matter 
abnormality similar to periventricular leucomalacia 
(webappendix p 6). Brain MRS in three children (patients 
1, 2, and 11) did not show any abnormalities.
SLC6A3 gene mutations were identiﬁ ed in all patients 
(table 2). Mutations identiﬁ ed in patients 1–3 have been 
reported previously,9 and novel SLC6A3 mutations were 
detected in patients 4–11. No mutation hotspots were 
noted. Within each patient’s family, identiﬁ ed mutations 
segregated appropriately with dopamine transporter 
deﬁ ciency syndrome disease status (parents obligate 
heterozygote carriers, unaﬀ ected siblings either wild 
type or carriers). None of the identiﬁ ed mutations was 
reported as a polymorphism in genomic databases or 
was detected from analysis of more than 300 control 
chromosomes matched for ethnic origin. Sequence 
alignment for novel missense mutations showed Val158, 
Gly327, Arg521, Pro529, and Pro554 to be highly 
conserved throughout vertebrate species, and Leu224 to 
be highly conserved throughout mammalian species 
(webappendix p 7). The deletion and nonsense mutations 
were predicted to result in nonsense-mediated decay 
(and no expression of DAT), or a truncated protein 
product. Patients 4 and 6 were homozygous for splice 
variants predicted to cause aberrant splicing according 
to the Berkeley Drosophila Genome Project’s Splice Site 
Prediction. In patient 8, exons 12 and 13 failed to amplify 
on repeated occasions, suggesting a homozygous 
deletion. Long-range PCR was used to characterise the 
putative deletion and deﬁ ne the genomic deletion 
breakpoint (webappendix pp 8–9).
For all identiﬁ ed missense mutations, the transport 
activity of mutant hDAT proteins was compared with 
Figure 2: Expression of wild-type and mutant human dopamine transporter 
in HEK293 cells
Protein was probed with antibodies against the C-terminal (A) and 
N-terminal (B) of the dopamine transporter, and with anti-β-actin antibody to 
show the relative equivalent loading of total protein (C). The same amount of 
total lysate protein was loaded in all lanes. The mutations not reported in 
previous studies are shown in the same sequence as in webappendix p 10, 
starting with patient 5.
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that of wild-type hDAT (webappendix p 10). Wild-type 
hDAT had normal transport activity, but the mutant 
proteins showed either non-speciﬁ c uptake (Leu368Gln, 
Pro395Leu, Val158Phe, Pro554Leu, Gly327Arg, 
Gly327Arg plus Gln439X, and Leu224Pro) or lower 
uptake than that of wild-type hDAT (6% of wild-type 
activity for Pro529Leu, and 27% of wild-type activity for 
Arg521Trp). Coexpression of Gly327Arg plus Gln439X 
with Pro529Leu (as in patient 9) further lowered activity 
to non-speciﬁ c uptake. The Kd of ³H-CFT was near 
normal in the mutants at 13–44 nM (17 nM in wild type) 
apart from in the Gly327Arg plus Gln439X mutant, for 
which binding was substantially lower, with a higher Kd 
of 101 nM. In many mutants, non-speciﬁ c binding of 
³H-CFT was higher than in wild type, contributing to 
greater than normal variation in the data. The Ki of 
dopamine in inhibition of cocaine-analogue binding was 
near that of wild-type hDAT in the mutants Pro395Leu, 
Pro554Leu, Gly327Arg, Pro529Leu, and Arg521Trp, but 
was reduced (higher Ki) in the Leu368Gln mutant and, 
to a lesser extent, in the Gly327Arg plus Gln439X and 
Leu224Pro mutants. Maximal binding of ³H-CFT to 
cells, mainly representing surface binding,15 indicated 
decreases of three–ﬁ ve times in mutants Leu368Gln, 
Pro554Leu, Gly327Arg plus Gln439X, Pro529Leu, and 
Arg521Trp, and, to a lesser extent, in the Pro395Leu 
mutant, whereas decreases of 15 times or more were 
recorded in the mutants Val158Phe, Gly327Arg, and 
Leu224Pro (webappendix p 10).
Analysis of whole cell lysates by immunoblotting with 
anti-C-terminal DAT antibody showed deﬁ ciency in 
mature DAT (80 kDa) in the novel mutants Val158Phe, 
Pro554Leu, Pro529Leu, Leu224Pro, and Arg521Trp 
(ﬁ gure 2A), and in the previously studied mutants 
Leu368Gln and Pro395Leu.9 By contrast, Gly327Arg 
resembled wild type with a stronger band of mature DAT 
than in the other mutants. As expected, the Gly327Arg 
plus Gln439X mutant with the C-terminal deleted did not 
show a signal with anti-C-terminal DAT antibody 
(ﬁ gure 2A), but some expression of this mutant was 
detected with anti-N-terminal DAT antibody in the form 
of low-molecular-weight bands (ﬁ gure 2B). For all other 
mutants, the patterns recorded with anti-terminal DAT 
antibody (ﬁ gure 2B) were identical to those recorded with 
antibody to the C-terminal. The Val158Phe mutant had 
particularly low expression.
Panel: Research in context
Systematic review
In 2009, we identiﬁ ed SLC6A3 mutations in three children 
with infantile parkinsonism-dystonia.9 We searched PubMed 
and could not ﬁ nd a similar study characterising this 
autosomal recessive genetic disorder.
Interpretation
Detailed clinical and molecular analysis of a cohort of children 
with dopamine transporter deﬁ ciency syndrome has allowed 
comprehensive delineation of this newly recognised clinical 
disorder. Our ﬁ ndings conﬁ rm that hereditary dopamine 
transporter deﬁ ciency syndrome is a novel neurotransmitter 
disorder caused by loss-of-function mutations in the gene 
encoding the dopamine transporter (SLC6A3), resulting in an 
early-onset severe motor disorder.
Figure 3: Diagnostic algorithm for dopamine transporter deﬁ ciency syndrome and diﬀ erential disorders
CSF=cerebrospinal ﬂ uid. Neurometabolic investigations need to be tailored according to the clinical presentation, but could include serum assessment of lactate, ammonia, biotinidase, carnitine, 
acylcarnitine proﬁ le, aminoacids, thyroid function tests (including free triiodothyronine); urine assessment of organic acids, aminoacids, purines, and pyrimidines; and CSF assessment of lactate, 
glucose, aminoacids, and protein. Assessment of a muscle or skin biopsy sample, specialist metabolic tests, and genetic investigation might also be appropriate. A CSF neurotransmitter proﬁ le should 
include homovanillic acid, 5-hydroxyindoleacetic acid, and pterins.5,21
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Discussion
We report a detailed description of a precisely diagnosed 
series of children with autosomal recessive dopamine 
transporter deﬁ ciency syndrome, a complex movement 
disorder, which we have shown is associated with loss-of-
function mutations in the SLC6A3 gene (panel). 
Dopamine transporter deﬁ ciency syndrome is thus a 
dopamine transportopathy and is the ﬁ rst identiﬁ ed 
disorder with parkinsonian features due to genetic 
alterations of DAT.6 Because inherited diseases are often 
named after the underlying pathogenic defect, we now 
refer to this disorder as hereditary dopamine transporter 
deﬁ ciency syndrome as an indication of the underlying 
disease mechanism and to encompass the range of 
clinical phenotypes.
In this study, we showed loss of DAT function in 
dopamine transporter deﬁ ciency syndrome. All mutations 
that were predicted to result in expression of hDAT protein 
severely incapacitated dopamine transport. Mechanisms 
underlying the loss of DAT transport function include 
reduced expression of DAT, loss of dopamine recognition 
by DAT due to reduced binding aﬃ  nity, and lack of 
glycosylation to form mature DAT, which is known to 
negatively aﬀ ect traﬃ  cking to the cell surface and transport 
function of DAT.16 Homology modelling of these point 
mutants, based on the structure of the bacterial analogue 
LeuT,17 shows subtle structural changes compared with 
wild type. These changes are far distal from the mutated 
residue and could aﬀ ect conformational changes needed 
during dopamine transport (data not shown). The ﬁ ndings 
of in-vivo DaTSCAN imaging in patient 3 are consistent 
with the in-vitro assessment of DAT function, providing 
further evidence that loss of DAT function has a causative 
role in the pathogenesis of dopamine transporter 
deﬁ ciency syndrome.
In dopamine transporter deﬁ ciency syndrome, we 
postulate that defective reuptake of dopamine into the 
presynaptic neuron causes accumulation of extraneuronal 
dopamine, thus resulting in dopamine degradation6 and 
raised concentrations of homovanillic acid in CSF 
neurotransmitter analysis. Dopamine transporter defects 
do not aﬀ ect the serotonin biosynthetic pathway and 
concentrations of 5-hydroxyindoleacetic acid in CSF are 
normal in dopamine transporter deﬁ ciency syndrome, 
Dopamine transportopathy Dopamine biosynthesis defect
Clinical syndrome Dopamine transporter deﬁ ciency 
syndrome
Autosomal recessive GTP cyclohydrolase deﬁ ciency; autosomal 
dominant GTP cyclohydrolase deﬁ ciency (classically milder); pyruvoyl-
tetrahydropterin synthase deﬁ ciency; sepiapterin reductase deﬁ ciency; 
dihydropteridine reductase deﬁ ciency; tyrosine hydroxylase deﬁ ciency; 
or aromatic acid decarboxylase deﬁ ciency
Age of onset Infancy Usually infancy (rarely after the infantile period)
Clinical features
Early irritability Yes Yes
Feeding diﬃ  culties, swallowing diﬃ  culties Yes Yes
Bulbar dysfunction Yes Yes
Global developmental delay Yes Yes
Truncal hypotonia Yes Yes
Prominent extrapyramidal symptoms 
(dystonia, choreoathetosis, parkinsonism, 
tremor, and oculogyric crises)
Yes Yes
Autonomic features (hyperthermia, 
sweating, hypersalivation, sleep disturbance)
Yes Yes
Pyramidal tract features Yes Yes
Diurnal variation of symptoms Not reported in children older than 
3 years (in whom diurnal variation 
would be assessable)
Might be evident (eg, GTP cyclohydrolase deﬁ ciency)
Microcephaly Not often reported Reported
Seizures Not reported Reported
Ocular features
Oculogyric crises Reported in a few patients Often reported
Ocular ﬂ utter and saccade initiation failure In most patients Not reported
Dystonic storms or status dystonicus Often reported Rarely reported
CSF neurotransmitter analysis Raised ratio of homovanillic acid to 
5-hydroxyindoleacetic acid
Reduced homovanillic acid, reduced 5-hydroxyindoleacetic acid, or 
abnormal pterins, or a combination
Clinical response to therapeutic agents Partial and temporary Can be substantial in some dopamine biosynthesis defects (eg, levodopa 
in tyrosine hydroxylase deﬁ ciency and GTP cyclohydrolase deﬁ ciency)
CSF=cerebrospinal ﬂ uid.
Table 3: Comparison of dopamine transporter deﬁ ciency syndrome with infantile neurotransmitter disorders of dopamine biosynthesis
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leading to an increased ratio of homovanillic acid to 
5-hydroxyindoleacetic acid in CSF. Poor dopamine 
reuptake leads to depleted presynaptic stores of 
intracellular dopamine to be packaged into synaptic 
vesicles for release extraneuronally with perisynaptic 
diﬀ usion.6,18 Excess extraneuronal dopamine might also 
overstimulate presynaptic D2 autoreceptors (D3 receptors), 
resulting in inhibition of tyrosine hydroxylase and 
thereby decreasing dopamine production.6 Excess 
extraneuronal dopamine might additionally have 
postsynaptic eﬀ ects, such as downregulation or 
desensitisation of postsynaptic dopamine receptors, with 
alterations in downstream signalling. Many of these 
physiological consequences of transporter dysfunction 
are evident in mutant mice lacking DAT and other 
monoamine transporters.19
Many patients with dopamine transporter deﬁ ciency 
syndrome are likely to be undiagnosed. In many centres, 
CSF neurotransmitter analysis might not be a routine 
investigation for children with a complex motor 
disorder.20 Furthermore, because dopamine transporter 
deﬁ ciency syndrome is rare and some of its clinical 
features are present in several infantile neurological 
syndromes, a deﬁ nitive diagnosis cannot be made on 
clinical grounds alone. The clinical presentation of 
dopamine transporter deﬁ ciency syndrome can mimic 
dyskinetic, spastic, and mixed cerebral palsy. The 
diﬀ erential diagnosis of dopamine transporter deﬁ ciency 
syndrome also includes disorders of dopamine 
biosynthesis,21 neurodegenerative disorders, such as 
neurodegeneration with brain iron accumulation,22 and 
early-onset neurometabolic syn dromes, such as 
mitochondrial diseases.23 For accurate diagnosis of 
dopamine transporter deﬁ ciency syndrome, the key 
clinical features need to be recognised and followed by 
appropriate biochemical and genetic investigations 
(ﬁ gure 3).
The features of dopamine transporter deﬁ ciency 
syndrome seem to result from dopamine dysregulation, 
which might eventually result in cerebral dopamine 
deﬁ ciency.21,24,25 Several other infantile neurotransmitter 
disorders caused by enzyme defects in the pterin and 
dopamine biosynthetic pathway also result in dopamine 
deﬁ ciency (table 3).5,21 Therefore, the fact that dopamine 
transporter deﬁ ciency syndrome shares many clinical 
features reported in such disorders is not surprising, but 
dopamine transporter deﬁ ciency syndrome and 
dopamine biosynthesis disorders also have distinct 
clinical, biochemical, and therapeutic diﬀ erences 
(table 3). Most importantly, the raised ratio of homovanillic 
acid to 5-hydroxyindoleacetic acid in CSF does not occur 
in any other disorder of dopamine metabolism and is 
therefore a key ﬁ nding for the diagnosis of dopamine 
transporter deﬁ ciency syndrome.
Therapeutic strategies have either little or no eﬀ ect on 
the clinical symptoms of dopamine transporter deﬁ ciency 
syndrome, unlike some dopamine biosynthesis disorders. 
Notably, the two patients who showed a clinical response 
to cocareldopa (patients 9 and 11) had mutations that 
were shown to be associated with some residual DAT 
activity on functional investigation. Characterisation of 
further cases of dopamine transporter deﬁ ciency 
syndrome will allow improved interpretation of whether 
genotype can predict phenotype (disease severity or 
response to drug treatment). In this study, use of the 
dopamine receptor agonists ropinirole and pramipexole 
(used in adult-onset Parkinson’s disease26) in patients 
with dopamine transporter deﬁ ciency syndrome had 
some beneﬁ t, but the optimum paediatric dose, side-
eﬀ ect proﬁ le in the paediatric population, and eﬀ ect on 
long-term outcome need to be established. Future 
neuromodulatory therapeutic strategies, with dopamine 
agonists and deep brain stimulation,27 might need to be 
used early in the disease course before the postulated 
compensatory changes in postsynaptic signalling 
pathways have occurred.
We have delineated the clinical, molecular genetic, 
and functional features of a novel disorder. Increased 
recognition of dopamine transporter deﬁ ciency 
syndrome will expand the range of phenotypes 
identiﬁ ed, allow accurate diagnosis and genetic 
counselling, prevent unnecessary investigations, provide 
further insights into genotype–phenotype correlations 
and DAT function, and accelerate the development of 
therapeutic strategies.
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